Analyst picks & changes

Amgen Inc.

Dillon, Read analyst Larry Bloom upgraded Amgen Inc. to "attractive" from "neutral," saying

Neupogen

G-CSF sales have recovered in the past

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE